Buy CNTB by Apr 2, 2027.

Setup over the next 6 months is interesting and maybe being ignored by the market. My thesis is based on a few possible catalysts: 1. China / Simcere approval catalyst CNTB’s partner Simcere has completed Phase 3 for rademikibart in atopic dermatitis in China, and the NDA was accepted by China’s NMPA in July 2025. If approved, CNTB could receive milestone payments upto 110 million dollars plus future double digit royalties. From what I understand, approval timelines in China can …